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Context: Heterozygous, de novo mutations in the transcription factor SOX2 are associated with
bilateral anophthalmia or severe microphthalmia and hypopituitarism. Variable additional ab-
normalities include defects of the corpus callosum and hippocampus.
Objective: We have ascertained a further three patients with severe eye defects and pituitary
abnormalities who were screened for mutations in SOX2. To provide further evidence of a direct
role for SOX2 in hypothalamo-pituitary development, we have studied the expression of the gene
in human embryonic tissues.
Results: All three patients harbored heterozygous SOX2mutations: a deletion encompassing the
entire gene, an intragenic deletion (c.70_89del), and a novel nonsense mutation (p.Q61X) within
the DNA binding domain that results in impaired transactivation. We also show that human SOX2
can inhibit -catenin-driven reporter gene expression in vitro, whereas mutant SOX2 proteins are
unable to repress efficiently this activity. Furthermore,we showthat SOX2 is expressed throughout
the human brain, including the developing hypothalamus, as well as Rathke’s pouch, the devel-
oping anterior pituitary, and the eye.
Conclusions: Patients with SOX2mutations often manifest the unusual phenotype of hypogona-
dotropic hypogonadism, with sparing of other pituitary hormones despite anterior pituitary hy-
poplasia. SOX2 expression patterns in human embryonic development support a direct involve-
ment of the protein during development of tissues affected in these individuals. Given the critical
role of Wnt-signaling in the development of most of these tissues, our data suggest that a failure
to repress the Wnt--catenin pathway could be one of the underlying pathogenic mechanisms
associatedwith loss-of-functionmutations in SOX2. (J Clin EndocrinolMetab 93: 1865–1873, 2008)
SOX2 (OMIM 184429) belongs to the SOX family of tran-scription factors that contain a 79-amino acid high mobil-
ity group (HMG) box DNA-binding domain similar to that
found in the sex-determining gene SRY (OMIM 480000) (1, 2).
SOX1 (OMIM 602148), SOX2, and SOX3 (OMIM 313430)
belong to the B1 subfamily and are expressed in various phases
of embryonic development and cell differentiation, inwhich they
play critical roles from the earliest stages of development (3, 4).
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In the mouse, Sox2 expression is first detected in cells at the
morula stage at embryonic d (E) 2.5 and then in the inner cell
mass of the blastocyst (E3.5) (5). After gastrulation, Sox2 ex-
pression becomes largely restricted to presumptive anterior neu-
roectoderm, and by E9.5 is expressed throughout the central
nervous system, sensory placodes, branchial arches, and gut
endoderm, including the developing esophagus (1, 6, 7).
Sox2/ null embryos die shortly after implantation; how-
ever, Sox2 heterozygous mice appear relatively normal, but
about one third show perinatal lethality, and others show a re-
duction in size and male fertility (5). We have recently demon-
strated a role for Sox2 in the development of the anterior pitu-
itary gland in the mouse. Analysis of heterozygous mutant mice
showedavariable hypopituitaryphenotypeaffecting the size and
shape of the pituitary gland, and a significant lowering of pitu-
itary GH, LH, ACTH, and TSH contents in affected mice (8).
Heterozygous mutations within SOX2 in humans have been
associated with bilateral anophthalmia or severe microphthal-
mia, in addition to hypopituitarism characterized by anterior
pituitary hypoplasia and gonadotropin deficiency (hypogona-
dotropic hypogonadism)with genital abnormalities inmales (7–
9). Additional forebrain defects may also include hypoplasia of
the corpus callosum, hypothalamic hamartoma, and hippocam-
pal malformation (8, 10), frequently associated with additional
abnormalities, including esophageal atresia, sensorineural hear-
ing loss, and learning difficulties.
We now report the endocrine phenotype in a further three
patients with de novo heterozygous mutations in SOX2, includ-
ing a novel mutation in the HMG box (p.Q61X), in addition to
an individual with an interstitial deletion of chromosome 3q26-
q27 encompassing the entire gene. We describe here for the first
time the expression pattern of SOX2 during human embryonic
development using in situ hybridization and immunohistochem-
istry. Inaddition,because thedisruptionofWnt signalingand the
normal function of-catenin have been associatedwith pituitary
defects in mice (11, 12), and because SOX proteins have been
reported to interact with -catenin (13, 14), we have used an in
vitro reporter system to show that several of the naturally oc-
curring mutations identified in patients impair the ability of hu-
man SOX2 to antagonize the transcriptional activity of
-catenin.
Patients and Methods
Patients (Table 1)
Patient 1
Patient 1 has previously been reported to show an unusual karyotype
consisting of a de novo translocation with an associated interstitial de-
letion of chromosome 3q at the break point: 46,XX,del (3) (q26.33q28)t
(3, 7) (q28;q21.1) (patient 2 in Ref. 15). This female patient was born to
nonconsanguineous parents at term by a normal vaginal delivery with a
birth weight of 1.42 kg [5.68 SD score (SDS)]. She had right anoph-
thalmia and left microphthalmia, and mild pulmonary stenosis. Global
developmental delay was noted at the age of 15 months. A right ocular
prosthesis was inserted and a corneal graft performed in the left eye.
Visual evoked responses and an electroretinogram revealed good retinal
and optic nerve function. Audiometry revealed normal hearing. TA
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Magnetic resonance imaging (MRI) revealed a hypoplastic anterior
pituitary, a normal infundibulum, an eutopic posterior pituitary, and a
thin corpus callosum with prominent ventricles and some frontotempo-
ral volume loss (Fig. 1). Subsequently, growth velocitywas poor over the
first 18 months (height 65.7 cm, 5 SDS; weight 5.54 kg, 4.36 SDS;
height velocity2 SDS between the ages of 0.5 and 1.55 yr). Investiga-
tions revealed a peak GH of 26.8 g/liter (67.2 mU/liter), with a normal
cortisol of 24g/dl (670nmol/liter), normal prolactin [12.1g/liter (242
mU/liter)], and normal thyroid function [free T4 (FT4) 1.5 ng/dl (19.4
pmol/liter); peak TSH to TRH 23.5 mU/liter]. Gonadotropin deficiency
could not be excluded (peak LH to LHRH 3.5 IU/liter, peak FSH to
LHRH at 60 min of 7.8 IU/liter at 20 months age). Subsequently, her
height velocity ranged from 1.93 to 2.7 SDS but with an IGF-I and
its binding protein-3 concentrations of 227 ng/ml (1 SDS) and 3.30
mg/liter (0 SDS), respectively. The proband is now aged 6.5 yr, and no
endocrine treatment is required at present.
Patient 2
This female patient was referred to the pediatric endocrine service
aged nearly 19 yr due to a lack of pubertal development. She exhibited
bilateral anophthalmia, but no symptomsofwider pituitarydysfunction.
She had evidence of significant neurodevelopmental delay. She reported
a normal sense of smell, and there was no family history of delayed
puberty. She hadTanner stageV pubic hair, stage II axillary hair, mature
nipple development but no significant underlying breast tissue. Her
height was on the 9th centile, and the weight was between the 25th and
50th centiles. Investigations demonstrated a normal karyotype, early
morning urinary concentrating capacity (838 mOsm/kg), thyroid func-
tion [FT4 1.3 ng/dl (16.8 pmol/liter), TSH 1.3 mU/liter], cortisol [7.3
g/dl (201 nmol/liter); normal range (NR) 5–25 g/dl (138–690 nmol/
liter)], and IGF-I (264.6 ng/ml; NR 215–885 ng/ml) concentrations.
Basal gonadotropins were undetectable (both  1.0 U/liter), and in re-
sponse to anLHRHstimulation test, LH increased to 2.1U/liter andFSH
to 2.0 U/liter. A pelvic ultrasound showed a 3-cm length uterus, but no
ovaries were identified. These clinical, biochemical, and radiological
findings were interpreted to be in keeping with hypogonadotropic hy-
pogonadism. Her parents were reluctant for her to undergo intracranial
imaging given the likely need for sedation or anesthesia.
Patient 3
Patient 3 is a 14.5-yr-old girlwho is the second child of four offspring,
born to unrelated parents at full term after a pregnancy complicated by
uterine contractions in the fifthmonth thatwanedwith tocolytic therapy
that was maintained until delivery. The birth weight was 3.35 kg (0.5
SDS) and birth length 50 cm (0.38 SDS). She presented with bilateral
anophthalmia. At 15 d of life, she underwent corneal transplantation,
and brain MRI showed an arachnoid cyst in the suprasellar area, with
right deflection of the pituitary pedunculus. She was referred to the en-
docrinologist at the age of 9.4 yr because of short stature (height 125.8
cm, 1.31 SDS; weight 24.2 kg, 1 SDS). Investigations performed at
the age of 11.4 yr revealed normal thyroid function [FT4 1.01 ng/dl (13
pmol/liter), TSH 2.45mU/liter], and a peak GH response to clonidine of
14.1 g/liter (42.3 mU/liter) and to arginine stimulation of 10.2 g/liter
(30.6mU/liter). The IGF-I concentration was within theNR (312 ng/ml;
NR 97–699 ng/ml). Subsequent investigations at the age of 14.5 yr, at
which stage she had no evidence of puberty (height 2.58 SDS, weight
0.34 SDS), revealed gonadotropin deficiency with low basal gonado-
tropin concentrations (LH undetectable, FSH 0.6 IU/liter) and poor re-
sponses to GnRH stimulation (peak LH 2.6 IU/liter; peak FSH 2.7 IU/
liter). TRH testing performed at this time showed normal thyroid
functionwith normal TSH (peak 12.3mU/liter) and prolactin [peak 24.6
g/liter (492 mU/liter)] responses, and a normal FT4 [1.3 ng/dl (16.8
pmol/liter); NR 0.8–1.8] concentration. At the last outpatient visit, no
pubertal development had occurred, and estrogen replacement is cur-
rently being considered. There was no evidence of learning difficulties.
Mutation analysis
To detect chromosomal abnormalities, we used the Agilent 44k Hu-
man Genome CGH microarray (Agilent Technologies, Wokingham,
UK). Genomic DNA from patient 1 and reference normal human male
genomicDNA (PromegaCorp.,Madison,WI)were digested and labeled
incorporating either 3 mM Cy5-deoxyuridine 5-triphosphate (test sam-
ple) or Cy3-deoxyuridine 5-triphosphate (male reference). Purified Cy5-
and Cy3-labeled DNA was combined and mixed with human Cot-1
DNA (Invitrogen, Paisley, UK). Automated hybridization and washes
were performed in anHSPro 4800 ProHybridization Station (TecanUK
Ltd., Reading, UK). Slides were scanned using an Agilent microarray
scanner (Agilent), and data analysis was performed using Agilent Ana-
lytics v3.3.27 software.
For intragenic mutations, the coding sequence of SOX2 was ampli-
fied from genomic DNA and directly sequenced as described elsewhere
(8). Sequences were compared with SOX2 reference sequence (RefSeq
NM_003106). Ethical committee approval was obtained from the In-
stitute of ChildHealth/Great Ormond Street Hospital for Children Joint
Research Ethics Committee. Informed written consent was obtained
from the parents, and, where applicable, the patients before collection of
samples and genomic analysis.
Plasmid constructs
PCR products comprising the entire SOX2 coding region from pa-
tient 2 were generated and cloned into pcDNA3.1() (Invitrogen) and
pCMV/SV-Flag, containing an in-frameN-terminal FLAGepitope.Con-
structs containing wild-type SOX2, in addition to the mutations
c.60_61insG, c.387_388delC, and p.Q177X, have been previously de-
scribed (8). A clone containing the full-length human -catenin coding
sequence (CTNNB1; IMAGE Consortium CloneID 6151332) (16) was
obtained from Geneservice Ltd. (Cambridge, UK). To generate a con-
stitutively active phosphorylation mutant of -catenin, the mutation
c.96CA (p.S33Y) (17) was introduced using the QuikChange Site-
Directed Mutagenesis kit (Stratagene, La Jolla, CA).
Luciferase assay experiments
SOX2 luciferase reporter assays were performed using Chinese ham-
ster ovary cells as previously described (8). For the TOPFLASH assay
(18), human embryonic kidney 293 cells were cotransfected with 20 ng
FIG. 1. Midline sagittal MRI section of patient 1 showing hypoplasia of
the anterior pituitary (ap), normal infundibulum (i), with an eutopic
posterior pituitary (pp) and a thin abnormal corpus callosum (cc).
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TOPFLASH reporter, 30 ng-catenin expression construct, and increas-
ing amounts of wild-type SOX2 expression construct (1–70 ng). Lucif-
erase activity was measured using a BMG FLUOstar Optima multiplate
reader (BMG LABTECH Gmbh, Offenburg, Germany), and experi-
ments were each repeated three times independently and performed in
triplicate.
Cell localization studies
Chinese hamster ovary cells were transfected with 50 ng FLAG-
tagged SOX2 expression construct (wild type or p.Q61X). After trans-
fection, cells were washed, fixed, and immunostainingwas performed as
described elsewhere (8).
EMSA
SOX2 proteins were generated using the TNTQuick Coupled Tran-
scription/Translation System (Promega). EMSAs were performed as de-
scribed previously (8).
In situ hybridization
Analysis of human embryonic/fetal material was performed by the
Medical Research Council-Wellcome Trust Human Developmental Bi-
ology Resource in situ hybridization service with full ethical approval
from the Joint Great Ormond Street Hospital National Health Service
Trust/Institute of Child Health Ethics Committee.
Human embryos/fetuses at selected stageswere dissected and fixed in
4%paraformaldehyde, then dehydrated and embedded in paraffin wax.
Sections of 7 mwere cut using a standard microtome and mounted on
Superfrost Plus slides (BDH Laboratory Supplies, Poole, UK). In situ
hybridization was performed essentially as described by Wilkinson (19)
using digoxigenin incorporated riboprobes generated from a 697-bp
fragment of the 3 untranslated region of human SOX2 and cloned into
the pCR4-TOPOvector (Invitrogen). For antibodydetection, slideswere
incubatedwith antidigoxigenin antibody conjugatedwith alkaline phos-
phatase (diluted 1:1000, containing 2% fetal calf serum). Expression
patterns were visualized using the Nitro-Blue Tetrazolium Chloride/5-
Bromo-4-Chloro-3-Indolyphosphate p-Toluidine Salt system (Roche,
WelwynGardenCity, UK). Sectionsweremounted inVectaMount (Vec-
tor Laboratories, Burlingame, CA) and analyzed using the Axioplan2
imaging system (Carl Zeiss, Inc., Thornwood, NY).
Immunohistochemistry
Human embryo and fetal sections were dewaxed and rehydrated.
Antigen retrieval was performed by boiling for 10 min in 0.01 M citric
acid buffer (pH 6.0). After cooling to room temperature, slides were
transferred to Tris-buffered saline with Tween 20 (TBST) [0.5 M Tris
Base, 9% NaCl (pH 7.6), 0.025% Triton] and blocked with 10% heat-
inactivated rabbit serum (Sigma-Aldrich, St. Louis,MO) in TBST. Slides
were incubated with goat anti-SOX2 antibody (1:500 dilution; Immune
Systems Ltd., Paignton, UK) in TBST with 1% heat-inactivated rabbit
serum, thenwashed and incubatedwith a polyclonal rabbit antigoat IgG
biotinylated secondary antibody (1:100 dilution; Dako Corp., Carpin-
teria, CA). Biotin was detected using streptavidin-Alexa Fluor 555 con-
jugate in PBS (1:300dilution;Molecular Probes, Inc., EugeneOR). Slides
were mounted in Vectashield with DAPI (Vector Laboratories) and im-
ages captured on a Leica DC500 microscope using Fire Cam Software
(Leica Microsystems GmbH, Wetzlar, Germany).
Results
Mutation analysis
Fluorescent in situ hybridization analysis of patient 1 showed
that SOX2was deleted on the der(3) chromosome of the patient
in allmetaphase preparations examined (Fig. 2A). Subsequently,
microarray comparative genomic hybridization analysis defined
the extent of the deletion to approximately 7.8 Mb of chromo-
somal region 3q26.33-q27.3 (start: 181216930 bp; end:
189014508 bp) (Fig. 2B). The array CGH data showed no other
significant copy number changes.
Two other individuals were found to harbor de novo het-
erozygous mutations in SOX2. In patient 2 we identified the
novel transition c.181CT (Fig. 2C), resulting in the nonsense
mutation p.Q61X, which is predicted to result in a mutant pro-
tein truncated within theHMGdomain. This mutation creates a
BfaI restriction site that was used to genotype the parents of the
affected individual, neither of whom carried the mutation (Fig.
2C). Patient 3 was found to harbor a deletion of 20 nucleotides
upstream of the HMG domain (c.70_89del), which occurred de
novo in this individual because it was not present in her unaf-
fected parents (data not shown).
Molecular analysis of SOX2 mutations
The single exon structure of SOX2 implies that nonsense-
mediated decay mechanisms are unlikely to result in degra-
dation of the mutant transcript (20, 21). Therefore, we sought
to confirm the functional consequence of the p.Q61X muta-
tion in vitro. Luciferase reporter assays using a reporter con-
struct previously shown to be activated by SOX2 in vitro (8)
showed that the mutant construct failed to activate this re-
porter (Fig. 2D) as a result of the complete loss of DNA bind-
ing, compared with wild-type SOX2 (Fig. 2E). We also inves-
tigated the localization of the mutant protein within the cell.
Whereas the majority of wild-type SOX2was localized within
the cell nucleus, the p.Q61X mutant protein showed predom-
inantly cytoplasmic staining (Fig. 2F). The c.70_89del muta-
tion has previously been identified in other unrelated individ-
uals and shown to result in the loss of function of the predicted
protein product (8, 22, 23).
Previous studies have demonstrated that murine Sox2 is
capable of interfering with the activity of a -catenin respon-
sive promoter containing TCF/LEF binding sites mediated by
the COOH terminal portion of Sox2 outside of the DNAbind-
ing HMG domain (13). To investigate the ability of human
SOX2 to repress -catenin-TCF-mediated transcription, we
performed a TOPFLASH reporter assay (18). Cotransfection
of the reporter with an expression construct containing hu-
man -catenin leads to increased activation of the reporter.
Cotransfection with increasing amounts of wild-type human
SOX2 led to a dose-dependent reduction in -catenin induced
activation, whereas SOX2 alone had no effect on transcrip-
tional activation of the reporter (Fig. 3A). To determine the
effect of various naturally occurring truncating mutations in
SOX2, we cotransfected SOX2 expression constructs con-
taining the mutations c.60_61insG, p.Q61X, c.387_388delC,
and p.Q177X (c.529CT); the latter two maintain an intact
HMG domain and retain the ability to bind DNA in vitro (8).
Products from all four of these mutations failed to repress
-catenin-mediated transcription (Fig. 3B). Repeating the ex-
periments using a constitutively active -catenin mutant con-
struct (17) showed identical results to wild-type -catenin
(data not shown).
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Analysis of SOX2 expression during human embryonic
development
To understand the consequences of SOX2mutations directly
involved in specific tissue abnormalities, it is important to es-
tablish its expression patterns during human development. To
assess this, we analyzed available sections of normal human em-
bryos fromCarnegie Stage (CS) 14 through to fetal stage (F) 2 [
4.5- to 9-wk development (24)]. Expression of SOX2 mRNA
andproteinwas observed throughout the central nervous system
at all stages investigated. Strong expression is observed in the
forebrain at CS16, which is maintained throughout embryonic
development (Fig. 4,A–E),withSOX2 transcripts detected in the
cortex and neuroepithelium of the lateral ventricles at Fs (data
not shown).SOX2 expression isobservedwithinRathke’spouch
atCS16 (Fig. 4,AandB), andexpression ismaintainedwithin the
pouch and throughout anterior pituitary development, in addi-
tion to the overlying presumptive hypothalamus and generally
within neural ectoderm. SOX2 transcripts and protein are also
FIG. 2. Analysis of SOX2 mutations. A, SOX2 gene deletion in patient 1. Metaphase chromosomes were hybridized with BAC clone RP11–43F17
containing SOX2 (red signal; arrowhead) and a chromosome 3 centromeric clone (green signal). The normal chromosome 3 shows both red and green
signals. The der(3) shows only a green signal indicating that one copy of SOX2 is deleted. B, Array-CGH profile from patient 1. The chromosome 3
ideogram (left) and enlargement of the deleted region (right) show the ratio of probes (each represented by a single dot) plotted as a function of
chromosomal position; loss of copy number of a probe shifts the ratio to the left. C, Electropherogram showing the c.181CT transition (p.Q61X) in
patient 2 (arrow). BfaI digestion of PCR products showing that the heterozygous mutation occurred de novo in patient 2 (filled circle) and is not present
in the unaffected parents or in a normal control individual [wild type (WT)]. M, 100-bp DNA ladder. D–F, Functional effects of the p.Q61X mutation. D,
The p.Q61X mutation failed to activate the reporter showing similar levels of activation to empty expression vector compared with wild-type SOX2. E,
EMSA of wild-type and p.Q61X SOX2 proteins shows that the mutant SOX2 is unable to bind DNA. F, The p.Q61X mutation results in impaired nuclear
localization of the mutant protein compared with wild-type SOX2, which stains predominantly within the nucleus. DAPI, 4,6-diamidino-2-phenylindole;
IVT, in vitro translated empty expression vector.
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present within the cells lining the lumen of thematuring anterior
glandduring Fs (Fig. 4,C andD; data not shown).No expression
was observed in the infundibulum or posterior pituitary.
SOX2 is expressed throughout the telencephalon,with strong
expression in the region of the primordial hippocampus dentate
gyrus (data not shown). The midbrain and hindbrain also stain
uniformly for SOX2, including the developing cerebellumand in
the isthmic area of the midbrain-hindbrain boundary at CS19
(Fig. 4E). In later stages of fetal development, SOX2 is expressed
abundantly in the thalamus, and specific populations of SOX2
positive cells are detected throughout the hypothalamus, which
may represent neuronal and/or glial cell populations (Fig. 4,
F–H). SOX2 also shows significant expression along the entire
length of the developing neural tube, in addition to the dorsal
root ganglia in sections analyzed from CS14–CS20 (data not
shown).
Expression of SOX2wasobserved during eye development at
all stages investigated betweenCS16 and F2. At CS16, low levels
of SOX2 expression are detected in the developing lens vesicle
(Fig. 4I) andproximallywithin thedevelopingneural retina,with
a boundary of expression at the distal region of the retina. By
CS20, andduringFs thereafter,SOX2 expression is limited to the
inner layer of the neural retina, and is also present in the optic
nerve (Fig. 4J). Expression within the lens appears to be main-
tained at low levels as the lens differentiates, becoming unde-
tectable by in situ hybridization after F2 (9-wk development;
data not shown). SOX2 is also expressed within the cells lining
the nasal epithelium where SOX2 continues to be detected dur-
ing fetal development, in addition to the developing laryngo-
pharynx extending ventrally at the point of division of the tra-
chea and esophagus, as well as in the embryonic lung (Fig. 4, K
and L; data not shown).
In situ hybridization and immunohistochemistry failed to de-
tect the presence of SOX2 within the developing gonad from
CS14 onwards. UsingRTPCRanalysis, we detected SOX2 tran-
scripts in total RNA extracted from the developing gonads of
both males, from 7 wk (the earliest material available) through
to 12 wk, and females at 10-wk development (data not shown).
Strong expression was observed in the epithelium lining the lu-
men of the stomach and gut endoderm. No expression was ob-
servedby in situhybridization in theheart, kidneys, liver, adrenal
glands, or pancreas at any stage investigated (data not shown).
Discussion
Heterozygous, de novo mutations in SOX2 were initially de-
scribed in patients associated with severe bilateral eye malfor-
mations, most commonly anophthalmia (9, 25). We have re-
cently reported the additional phenotype of hypopituitarism in
six (of six) patients with mutations in SOX2 with anterior pitu-
itary hypoplasia and hypogonadotropic hypogonadism (8).
Here, we report an additional two patients who manifest hy-
pogonadotropic hypogonadism with lack of pubertal develop-
ment. To date, all eight patients with SOX2 mutations in our
cohort in whom a confirmed diagnosis can be made (excluding
patient 1 in this study) manifest hypogonadotropic hypogonad-
ism. Sato et al. (26) also recently reported a female patient with
unilateral anophthalmia and isolated hypogonadotropic hypo-
gonadism, suggesting that all individuals harboring SOX2 mu-
tations are at high risk for gonadotropin deficiency, which has
important implications for their clinical management. Patient 1
is as yet too young for a diagnosis of hypogonadotropic hypo-
gonadismat this stage, however, several aspects of thephenotype
exhibited by this patient are entirely consistent with phenotyp-
ical featuresobserved inotherpatientswithSOX2mutations (8).
Continued follow-up of this and other individuals with SOX2
mutations and timely diagnosis of sex steroid deficiency would
lead to prompt treatmentwith the prevention of associated long-
term morbidity.
Mice with a heterozygous disruption of Sox2 also display
endocrine deficits andhypoplasia of the anterior pituitary;more-
over, SOX2 is expressed in the developing hypothalamus and
FIG. 3. SOX2 disrupts -catenin-TCF/LEF mediated transcriptional
activation. A, Human embryonic kidney 293 cells were cotransfected with
the TCF/LEF reporter construct TOPFLASH with human SOX2 expression
construct alone (70 ng) or human -catenin expression construct with
variable amounts of SOX2 (1–70 ng). Increasing amounts of SOX2 led to
dose-dependent repression of -catenin-mediated activation of the
reporter. B, SOX2 mutations disrupt the interaction with -catenin. SOX2
mutant constructs were tested and compared with wild-type (WT) SOX2
using 20 ng TOPFLASH, 30 ng -catenin, and 20 ng SOX2 expression
construct. Truncating SOX2 mutations fail to repress -catenin-mediated
activation, showing levels of activation comparable to cotransfection with
-catenin alone or empty expression vector. Schematic representation of
the SOX2 gene with approximate positions of the mutations is shown in
the top right.
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Rathke’spouch inbothmiceandhumans, suggestingadirect role
for the gene in hypothalamo-pituitary development in both spe-
cies. The phenotype observed in patients of anterior pituitary
hypoplasia with isolated gonadotropin deficiency is unusual,
particularly because other pituitary hormone axes appear to be
clinically unaffected in the majority of patients, although a few
patients do exhibit GH insufficiency. It is of interest to note that
SOX2 expression is notuniform in thedevelopinghypothalamus
in humans (Fig. 4, G and H), suggesting that haploinsufficiency
for SOX2 may affect only certain populations of glia, neuroen-
docrine neurons, their progenitors, or their afferent inputs. The
report of a patient with isolated hypogonadotropic hypogonad-
ism without pituitary hypoplasia on imaging (26) suggests that
SOX2might be involved independently at multiple levels during
the development of the hypothalamo-pituitary-gonadal axis. Be-
cause mice with haploinsufficiency of Sox2 show more general-
ized pituitary deficits, the apparent selectivity for SOX2 muta-
tions impairing the gonadotrope axis in human subjects remains
intriguing.
The ocular phenotype associated with SOX2 mutations is
fully penetrant in all patients described to date; however, this
may be a result of ascertainment bias with patients selected for
screening based on the manifestation of bilateral anophthalmia
or microphthalmia. On the other hand, we have previously
screened a cohort of 235 patients with varying degrees of hy-
popituitarism and eye defects, and only identified pathogenic
mutations in those with bilateral anophthalmia/microphthal-
mia. More recently, we have not detected any coding sequence
variations in SOX2 in a small cohort of patients (n  20) with
isolated hypogonadotropic hypogonadism (data not shown).
The manifestation of hypogonadotropic hypogonadism with
unilateral eye disease and no other obvious neurological defects
in the patient described by Sato et al. (26) suggests that in hu-
mans, the hypothalamo-pituitary-gonadal axismaybemore sen-
sitive to SOX2 levels, or timing of expression, than other tissues.
Consistent with this, we note that mice do not display an eye
phenotype unless the level of Sox2 expression is reduced to levels
less than 40% that of wild type (27), whereas heterozygous
knockout mice do exhibit abnormal pituitary morphogenesis
and endocrine deficits (8).
It is always difficult to assign quantitative loss of function to
different mutations based on in vitro model assays on a single
reporter target, but there is good reason to suppose that the
effects we report on the -catenin/Wnt signaling pathway could
be relevant. Previous studies have shown that murine Sox2, as
well asXenopusXSox3,XSox17, andXSox17, are capable of
FOG. 4. SOX2 expression pattern in human embryonic and fetal tissue (mRNA: A–C, E, F, and I–L; protein: D, G, and H). Transverse (A) and sagittal (B)
sections show expression of SOX2 within the developing Rathke’s pouch (Rp) and overlying neural ectoderm at CS16 and CS19, respectively. C and D,
Coronal sections of F2 tissue showing SOX2 transcripts and protein continue to be expressed in the cells lining the lumen of the anterior pituitary (AP).
Note the absence of expression in the infundibulum (inf) and posterior pituitary (PP). E, Transverse section showing SOX2 expression in the forebrain,
including the region of the presumptive hippocampus (arrowhead), and throughout the midbrain and hindbrain in addition to the cerebellum (Ce). F–H,
Transverse sections of the forebrain in human fetal tissues at approximately 8-wk development showing expression of SOX2 in the hypothalamus (Hyp).
H, Magnified section corresponding to the boxed region in G. I and J, Transverse sections showing expression of SOX2 in the lens (l) vesicle and
developing neural retina (nr) at CS16, where expression is restricted to the proximal inner layer, with a boundary of expression in the distal region
adjacent to the lens (arrowhead). J, Expression within the lens diminishes by CS20. SOX2 is also expressed in the nasal epithelium (K) and in the
tracheoesophageal tract (L), as shown in transverse section. Scale bars: 500 m (E); 300 m (B–D, F, G, J, and K); and 100 m (A, H, I, and L). Di,
Diencephalon; Me, mesencephalon; oc, oral cavity; Oe, developing esophagus; phy, presumptive hypothalamus; Rh, rhombencephalon; T, telencephalon;
Tr, developing trachea; 3V, third ventricle.
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associatingwith-catenin and repressing the activity of a-cate-
nin responsive reporter (13, 14, 28). This inhibitory activity is
mediated by the COOH terminal domain and is independent of
either the HMG domain or the ability to bind DNA. We have
shown that human SOX2 protein is also capable of inhibiting
-catenin-mediated reporter gene activation, and that several
naturallyoccurringdenovomutations, producing truncatedmu-
tant proteins of varying length, were unable to repress this ac-
tivity in vitro. Both the c.387_388delC and p.Q177Xmutations
retain the ability to bind DNA (8) but show impaired repression
of -catenin. This suggests that the ability of SOX2 to repress
transcription in this assay is not a result of competition for bind-
ing sites on the reporter construct.
Wnt--catenin signaling pathways provide key signals for
forebrain and pituitary development, andmembers of the Tcf/
Lef family of transcription factors show distinct patterns of
expression in the developing anterior pituitary gland. The
formation of a complex between -catenin and Prop1 medi-
ates the attenuation of expression of the transcriptional re-
pressor Hesx1, and simultaneous activation of the pituitary
specific transcription factor Pou1f1 (Pit1) (11); both of these
events are critical for the determination of specific hormone
secreting cell types (29–31). Furthermore, premature activa-
tion of -catenin signaling in the developing anterior pituitary
in mice results in complete loss of the gland by E13.5 (11).
Hesx1 is an interesting target in this context because it is also
implicated in Wnt signaling pathways during forebrain de-
velopment, demonstrated by the abnormal domain of Wnt1
expression and ectopic activation of Wnt/-catenin targets in
Hesx1 mutant embryos (12). Furthermore, the phenotype as-
sociated with mutations in HESX1 in humans is somewhat
reminiscent of that in individuals with SOX2 mutations, in-
cluding ocular abnormalities, anterior pituitary hypoplasia,
andmidline forebrain abnormalities (8, 32–34). Disruption of
these interactions with -catenin and consequent effects on
the regulation of -catenin target genes may be one mecha-
nism by which loss-of-function mutations in SOX2 can result
in such a pleiotropic phenotype.
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